Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Phathom Pharmaceuticals Sees FY2025 Sales $165.000M-$175.000M vs $159.818M Est

Author: Benzinga Newsdesk | August 07, 2025 09:48am
Phathom Pharmaceuticals (NASDAQ:PHAT) sees FY2025 sales of $165.000 million-$175.000 million vs $159.818 million analyst estimate.

Posted In: PHAT

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist